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[LETTER TO THE EDITOR
Delayed gadolinium enhancement and elevated
plasma brain natriuretic peptide are useful in dif-
ferentiating hypertrophic cardiomyopathy from
athlete’s heart
To the Editor,
Oka et al. [1] reported that symptomatic ven-
tricular tachyarrhythmia is associated with delayed
gadolinium enhancement in cardiac magnetic res-
onance imaging and with elevated plasma brain
natriuretic peptide (BNP) level in hypertrophic car-
diomyopathy (HCM). I wish to add that these two
modalities have another useful function, that is,
differentiating HCM from athlete’s heart—–a dif-
ferential diagnosis that is important although not
always easy to make [2].
Delayed gadolinium enhancement in cardiac
magnetic resonance imaging in patients with HCM
indicates areas of myocardial ﬁbrosis and scar-
ring and may be an arrhythmogenic substrate
[3]. It has also been implicated in promoting
heart failure in HCM [4]. On the other hand,
delayed gadolinium enhancement has been neither
reported nor expected in subjects with athlete’s
heart.
Elevated BNP levels represent a ﬁnal common
pathway for many cardiovascular pathologic states
including heart failure, cardiac arrhythmias, car-
diac hypertrophy, myocardial ischemia, myocardial
ﬁbrosis, and coronary endothelial dysfunction [5].
Recent studies showed that the amino-terminal
fragment of the prohormone BNP (NT-proBNP) has
a wider detection range and more stable struc-
ture compared to BNP [6]. Thus NT-proBNP has
become increasingly a more widely used assay
than BNP [7]. Godon et al. [8] recently reported
elevated NT-proBNP levels in patients with HCM
in contrast to normal values in healthy ath-
letes.It is vitally important to distinguish physiologic
left ventricular hypertrophy in athletes (‘‘athlete’s
heart’’) from pathologic left ventricular hypertro-
phy in HCM. This is particularly pertinent nowadays
0914-5087/$ — see front matter © 2009 Japanese College of Cardiolon view of the tragic, unexpected, and often highly
ublicized sudden cardiac death of top-level ath-
etes reported by the news media. Whereas HCM
s the commonest cause of sudden cardiac death
n young athletes, its occurrence in elite athletes
s extremely rare [2]. Although there are many
imilarities between athlete’s heart and HCM, dis-
inguishing the two is possible in the majority of
ases [2]. The addition of these two laboratory
arameters will contribute further to the deﬁnitive
esolution of this important differential diagno-
is.
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uthor’s reply
ear Dr Cheng,
Thank you for your comments on our work. As
ou mentioned, it is sometimes difﬁcult to dis-
inguish hypertrophic cardiomyopathy (HCM) from
thlete’s heart. Delayed gadolinium enhancement
DGE) in cardiac magnetic resonance (CMR) and
lasma brain natriuretic peptide (BNP) levels may
e useful to detect high risk HCM patients in
oung athletes. However, changes in these param-
ters may be smaller in young HCM patients than
n our study population (mean age 67.4 years).
oreover, cardiac hypertrophy progresses rapidly
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plasma BNP levels for diagnosing HCM in young ath-
letes.
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∗ Tel.: +81 798 45 6553; fax: +81 798 45 6551.n young people, especially in adolescence [1]. A
ingle examination of CMR and/or BNP may not
e sensitive enough to exclude high risk HCM in
oung people. Further studies are necessary to
stablish the usefulness of DGE in CMR and/or d
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